FDA grants orphan status for AlzeCure’s pain drug candidate

Endeavor BioMedicines Receives Orphan Drug Designation from the U.S. Food and Drug Administration and European Commission for Taladegib (ENV-101) for the Treatment of Idiopathic Pulmonary Fibrosis

FDA grants orphan status for AlzeCure’s pain drug candidate

The company completed a positive Phase IIa trial of the candidate for chronic subjects with peripheral neuropathic pain. It is now preparing for further clinical development and has The post FDA grants orphan status for AlzeCure’s pain drug candidate appeared first on Pharmaceutical Business review.